Latest1 information on COVID-19
©2022 Stanford Medicine
A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
Not Recruiting
Trial ID: NCT02595489
Purpose
In this pilot study, the investigators will assess the safety of two high-dose regimens of
oral vitamin D supplementation and measure the effects of vitamin D supplementation on
markers of oxidative stress and inflammation in the blood and brain of study participants
before, during, and after taking vitamin D supplements.
The goal of the study is to establish research measures (i.e. biomarkers) and an optimal dose
for vitamin D supplementation in boys with the X-linked adrenoleukodystrophy (ALD) genotype.
Official Title
A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy
Stanford Investigator(s)
Eligibility
Criteria for enrollment to screening:
1. Molecular confirmation of X-linked ALD (VLCFA elevation & ABCD1 mutation) known in
patient or immediate family member)
2. Male
3. Age 1.5yrs (i.e. 18mos) - 25yrs at screening
Criteria for assignment to drug:
1. Plasma 25-hydroxy vitamin D level ≤ 60ng/ml in past 30 days
2. MRI brain in past 6 months that is negative for evidence of active cerebral
demyelination
Exclusion Criteria:
- history of liver or kidney disease
- history of nephrolithiasis
- history of hyperthyroidism
- history of ulcerative colitis, Crohn's disease, celiac disease
- taking medication interfering with gastrointestinal absorption
- contraindication or inability to complete MRI every 6 months
Intervention(s):
dietary supplement: vitamin D3
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Keith Van Haren, MD